DRUG DEVELOPMENT
Applications of Biomolecular Interaction Analysis in drug development
Biomolecular Interaction Analysis (BIA) based on the physical principle of surface plasmon resonance (SPR) is utilised in nearly all phases of drug development. Thus, BIA is a valuable tool for getting high quality data of the binding of LMW compounds to a protein on the step of target identification, screening of potential hit molecules and candidate drug selection in the preclinical and clinical development.
BIA covers a broad range of applications including
- target identification/validation
- hit/lead identification/selection
- secondary screenings
- lead optimisation/characterisation
- early ADME assays
- candidate drug selection/characterisation
- immunogenicity studies
Assay development and functional binding assays for compound characterisation are the most commonly used applications of BIA in drug development.
Benefit from the advantage of SPR technology as label-free analysis in real time and yield highly reproducible kinetic data with low sample consumption.
Tel.: +49 (0) 561-804 4661 | Fax: +49 (0) 561-804 4665 | info@biaffin.de
We value your privacy
In order to optimize our website for you and to be able to continuously improve it, we use cookies. Further information is available in our Data Protection Statement. Here you can find our Legal Information.